Moderna (MRNA) stock gains 3.6% after FDA approves mFlusiva flu vaccine for adults 50+, but analysts see no major revenue until 2027. Details inside. The post Moderna (MRNA) Stock Rallies on FDA Green Light for mRNA Flu Shot appeared first on Blockonomi.